News-Medical.Net October 3, 2022
Sponsored Content by Sino Biological Inc. Reviewed by Alex Smith

In this interview, NewsMedical talks to Dr. Amy Sheng, a technical account manager at Sino Biological, and Dr. Lurong Pan, founder and CEO of next-generation biotech startup Ainnocence, about how artificial intelligence (AI) can be used in combination with high throughput production and screening to enhance the development process for potential universal vaccines.

Topics discussed include how AI can be used in combination with high throughput production and screening of proteins to expedite the development process for candidate universal vaccines – an ideal method for preventing and controlling future pandemics but also one of the major research challenges in biotechnology today.

Can you provide an overview of your background and your current role at Sino Biological and Ainnocence, respectively?

Dr....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Interview / Q&A, Pharma / Biotech, Technology, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article